40, Dalton St

Boston,

MA,

USA,

ZIP: 02115

Phone: +1 617 455 4188

With Karuna's schizophrenia program coined as the most anticipated drug launch of 2024, and 2023 bringing brand new regulatory guidance, surging investment has reinvigorated the space with new targets, mechanisms, and technologies to transform the mental health treatment landscape.

Capitalizing on a new wave of pipeline momentum, the 7th Neuropsychiatric Drug Development Summit returns as the industry's premier gathering, showcasing the latest circuit-based target innovation, EEG and digital biomarker data, in vivo and in vitro model advances, pioneering precision psychiatry approaches and more.

Join discovery, preclinical, translational, clinical, regulatory, and commercial experts from Karuna, Janssen, AbbVie, Otsuka, Sage Therapeutics, Lykos, Lundbeck, Compass, Biogen, Delix Therapeutics, and more as they address biopharma's most pressing challenges in a collaborative atmosphere to accelerate the race to approval for transformative neuropsychiatric candidates.


URLs:
Tickets: https://go.evvnt.com/2433814-2?pid=1052
Brochure: https://go.evvnt.com/2433814-3?pid=1052

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 3597.00,
Drug Developer Pricing - Conference Only: USD 2599.00,
Solution Provider Pricing - Conference + Workshop Day: USD 5197.00,
Solution Provider Pricing - Conference Only: USD 3699.00

Aaron Koenig, Chief Medical Officer, Delix Therapeutics, Ariana Mullin, Director, Regulatory Affairs, Bristol Myers Squibb, Ayan Ghoshal, Head of Neural Circuits, Associate Director, Biogen, Berra Yazar-Klosinski, Chief Scientific Officer, Lykos Therapeutics, Charmaine Lykins, Chief Commercial Officer, MapLight Therapeutics, Cornelia Dorner-Ciossek, Head of Digital Health TA CNS Retinopathies Emerging Areas, Boehringer Ingelheim, Dalibor Sames, Co-Founder, Gilgamesh Pharmaceuticals and Faculty, Columbia University, Daniel Karlin, Chief Medical Officer, Mind Medicine Inc., Daniel Smith, Executive Director and Head of Translational Medicine, Alkermes, Dina Burkitbayeva, Chief Executive Officer, Freedom Biosciences, Elemer Piros, Senior Managing Director, Rodman and Renshaw, Estibaliz Arce Cirauqui, Vice President - Translational Science and Clinical Development, Engrail Therapeutics, George Papakostas, Associate Executive Director, Clinical Trials Network and Institute, Massachusetts General Hospital, Gregory Ryslik, Chief Technology Officer, COMPASS Pathways, Guy Goodwin, Chief Medical Officer, COMPASS Pathways, Harald Murck, Apl. Professor, Philipps-Universität Marburg, Jackie von Salm, Co-Founder and Chief Scientific Officer, Psilera Bioscience, Jeffrey Brown, Chief Scientific Officer, Sensorium Therapeutics, Kevin Sanders, Executive Medical Director- CNS, Otsuka, Kjartan Frisch Herrik, Research Fellow, Lundbeck, Kurt Rasmussen, Chief Scientific Officer, Delix Therapeutics, Matt Kuntz, Vice President, Global Regulatory Strategy, Neuroscience, Abbvie, Matthew Harlin, Senior Director, CNS Discovery Research, Early Phase and Translational Medicine, Otsuka, Matthew Johnson, Senior Group Leader, The Broad Institute of MIT and Harvard, Michael McCully, Co-Founder, Gate Neurosciences, Inc., Michele Hummel Director, Early Phase Development and Translational Medicine, Otsuka, Moeen Panni, Head of Neuropsychiatry, Medical Affairs, Biogen, Nina Dedic, Senior Director, Head of CNS Pharmacology, Discovery Sciences, Sumitomo Pharma Oncology, Patricio O’Donnell, Vice President and Head of Translational Medicine, SAGE Therapeutics, Paul Imm, Senior Director, Global Regulatory Affairs - Neuropsychiatry, Janssen, Robert Discordia, Chief Executive Officer, Equulus Thrapeutics, Shaheen Lakhan, Chief Medical Officer, Click Therapeutics, Snezana Milanovic, Senior Director, TMED and Early Development, Sumitomo Pharma America Holdings, Inc., Stephen Brannan, Former Chief Medical Officer, Karuna Therapeutics, Steve Kanes, Chief Executive Officer, EmbarkNeuo, Umed Boltaev, Associate Research Scientist, Columbia University, Wayne Drevets, Vice President, Disease Area Team Leader, Neuroscience, Janssen, Zoë Hughes, Vice President, Head of Biology, Gilgamesh Pharmaceutical